Targeting cancer therapy combination

1. A conjugated complex, comprising:

a targeting compound; and

a chemical drug;

wherein said targeting compound is non-covalently complexed to said chemical drug via a redox agent as a reactant.

2. The conjugated complex of claim 1 , wherein the redox agent is selected from the group consisting of stannous chloride (SnCl 2 ), stannous sulfate (SnSO 3 ), stannous oxide (SnO), stannic oxide (SnO 2 ), sodium stannate (Na 2 SnO 3 ), sodium stannite (Na 2 SnO 2 ), stannic chloride (SnCl 4 ), thiostannate (SnS 3 ), and stannous sulfide (SnS).

3. The conjugated complex of claim 1 , wherein said targeting compound is selected from the group consisting of a carrier capable of delivering an agent to a targeted tissue, Sodium Dimercaptosuccinate (III) (DMSA-III), Sodium Dimercaptosuccinate (V) (DMSA-V), Sodium Pyrophosphate and Stannous Chloride for Injection (PYP), Methylene Diphosphonate for Injection (MDP), polymerized albumin, Mercaptoacetyltriglycine, Pentetic Acid and Stannous Chloride (DTPA), Sodium Glucoheptonate and Stannous Chloride, L,L-Ethyl Cysteinate Dimer and Stannous Chloride (ECD), Exametazime (HMPAO), Etifenin and Stannous Chloride, Sodium Phytate and Stannous Chloride, Cu(MIBI) 4 BF 4 (MIBI), α-methyltyrosine, MIBI (2-methoxy isobutyl isonitrile), 2-nitroimidazole, monoclonal antibodies and monoclonal antibodies against neoplasm, and a traditional Chinese drug extract selected from the group consisting of Bruceantin, Tetrandrine, thalicarpine and maytansine.

4. The conjugated complex of claim 3 , wherein said chemical drug is selected from the group consisting of cisplatin, carboplatin, calcium folinate, vincristine, methotrexate, fluorouracil, cytosine arabinoside (Ara-C), cyclophosphamide, epirubicin, doxorubicin rapid dissolution, mitomycin, etoposide, bleomycin A5.

5. The conjugated complex of claim 1 , wherein said chemical drug is selected from the group consisting of cisplatin, carboplatin, calcium folinate, vincristine, methotrexate, fluorouracil, cytosine arabinoside (Ara-C), cyclophosphamide, epirubicin, doxorubicin rapid dissolution, mitomycin, etoposide, bleomycin A5.

6. The conjugated complex of claim 1 , further comprising an anti-neoplasm agent.

7. The conjugated complex of claim 6 , wherein the anti-neoplasm agent is selected from the group consisting of an alkylating agent, an antimetabolite, a natural product, a platinum coordination complex, an anthracenedione, a substituted urea, a methylhydrazine derivative, an adrenocortical suppressant, a hormone, an antagonist, an anti-cancer polysaccharide, an herb extract and a traditional Chinese drug extract.

8. The conjugated complex of claim 1 , further comprising an immune response potentiator.

9. The conjugated complex of claim 8 , wherein the immune response potentiator is selected from the group consisting of Bacille Calmette-Guerin (BCG), Corynebacterium Parvum, Brucella abortus , glucan, levamisole, tilorone, an enzyme and a nonvirulent virus.

10. The conjugated complex of claim 1 , wherein the redox agent is SnCl 2 and the targeting compound is an organ- or neoplasm-targeting compound.

11. The conjugated complex of claim 1 , wherein the redox agent is SnCl 2 and the chemical drug is a compound having anticancer effects.

12. The conjugated complex of claim 1 , wherein the redox agent is from about 0.01% (w/w) to about 35% (w/w), the targeting compound is from about 1% (w/w) to about 98% (w/w), and the chemical drug is from about 1 mg/ml to about 80 mg/ml.

13. A kit comprising the conjugated complex of claim 1 .

14. An article of manufacture, comprising:

a) packaging material;

b) the conjugated complex of claim 1 ; and

c) a label indicating that the article is for treating neoplasms.

15. The conjugated complex of claim 1 , wherein said chemical drug is a chemotherapeutic agent.

16. A conjugated complex, comprising:

a targeting compound; and

a chemical drug;

wherein said targeting compound is non-covalently complexed to said chemical drug.